BCG016 / Biocytogen - LARVOL DELTA

A novel bispecific antibody-drug conjugate, BCG016, that targets 5T4 and MUC1, demonstrates robust preclinical antitumor activity (AACR 2026) - "BCG016, in combination with a TOP1 inhibitor linker-payload (BLD1102), exhibited enhanced efficacy in PDX models compared to parental ADCs, significantly outperforming benchmark ADCs targeting 5T4 and MUC1.ConclusionIn summary, we have developed a novel bispecific ADC that targets both 5T4 and the membrane-bound MUC1-C. BCG016 showed superior anti-tumor efficacy in PDX models, underscoring its potential as a new therapeutic option for tumors that co-express 5T4 and MUC1."

ADC • Bispecific • Preclinical • Colorectal Cancer • Oncology • Pancreatic Cancer • Solid Tumor • MUC1 • TOP1

BCG016, a first-in-class bispecific antibody-drug conjugate targeting 5T4 and MUC1, demonstrates potent preclinical anti-tumor activity (AACR 2024) - "Cytotoxicity assays indicate that BCG016 improved tumor cell killing in vitro compared to benchmark ADCs, and in vivo efficacy studies showed superior anti-tumor efficacy of BCG016 in patient-derived NSCLC xenografts compared to benchmark ADCs and parental ADC combination therapy.In summary, we have generated a novel bispecific ADC targeting 5T4 and the cleaved MUC1-C protein, which remains membrane-bound on tumor cells. The 5T4-MUC1 bsADC showed superior anti-tumor efficacy in PDX models and has the potential to be a novel therapeutic for 5T4 and MUC1 co-expressing tumors."

ADC • Bispecific • Preclinical • Breast Cancer • Colorectal Cancer • Gastrointestinal Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Pancreatic Cancer • Solid Tumor • MUC1